Rasgap derived peptide for selectively killing cancer cells
AssigneeUniversite de Lausanne
InventorsChristian Widmann, Jiang-Yang Yang, David Michod
Life of this patent
Estimating the term…
Abstract
The present invention relates to a peptide consisting in the N2 sequence of the RasGAP protein, a fragment thereof, or a variant thereof which enhances the ability of a drug to selectively kill cells. Furthermore, it relates to a pharmaceutical composition comprising as an active substance a pharmaceutically effective amount of said peptide.
Claims43
A pharmaceutical composition comprising
- i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid,
- ii) and a genotoxin,
- wherein said at least one peptide enhances the ability of said genotoxin to kill selectively cancer cells.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The method according to claim 40, wherein the cancer is selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, liposarcoma, neuroendocrine tumor, mesothelioma, schwanoma, meningioma, adenocarcinoma, melanoma, leukemia, lymphoid malignancy, squamous cell cancer, epithelial squamous cell cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, a tumor of the biliary tract, and head and neck cancer.
(canceled)
(canceled)
A kit for treating or preventing cancer in a subject comprising
- i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid;
- and
- ii) instructions for use of said at least peptide.
A method for enhancing apoptosis in a cancer cell, comprising contacting the cancer cell with
- i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid, and
- ii) a genotoxin,
- wherein said at last one peptide enhances the ability of said genotoxin to selectively kill said cancer cell.
A method for enhancing the sensitivity of a cancer cell to a genotoxin comprising contacting the cancer cell with at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid.
A method of treating or preventing cancer in a subject comprising administering to said subject
- i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid, and
- ii) a genotoxin,
- wherein said at least one peptide enhances the ability of said genotoxin to kill selectively cancer cells, such that said cancer is treated or prevented.
Dependencies are inferred from the claim text.